Evogene Ltd. | CIK:0001574565 | 3

  • Filed: 3/30/2018
  • Entity registrant name: Evogene Ltd. (CIK: 0001574565)
  • Generator: GoXBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/0001178913-18-001042-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/evgn-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001574565
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfRelatedPartyExplanatory

    NOTE 22: -
    BALANCES AND TRANSACTIONS WITH KEY OFFICERS AND CERTAIN SHAREHOLDERS

    a.
    2017 shareholders information refers to Monsanto which, to the best of the Company’s knowledge, hold approximately 6.4% of the Company's ordinary shares and is also a major customer (see also Notes 5, 21(c)).

    b.
    Balances:
     
    Balance at December 31, 2017:
     
       
    Key officers
    		    
    Certain shareholder
    		  
                 
    Receivables
    		  
    $
    -
    		    
    $
    337
    		  
    Other payables
    		  
    $
    468
    		    
    $
    -
    		  
     
    Balance at December 31, 2016:
     
       
    Key officers
    		    
    Certain shareholder
    		  
                 
    Receivables
    		  
    $
    -
    		    
    $
    283
    		  
    Other payables
    		  
    $
    285
    		    
    $
    -
    		  


    c.
    Benefits to directors:

       
    Year ended December 31,
    		  
       
    2017
    		    
    2016
    		    
    2015
    		  
                       
    Compensation to directors not employed by the Company or on its behalf
    		  
    $
    329
    		    
    $
    322
    		    
    $
    371
    		  
                             
    Number of directors received the above compensation by the Company
    		    
    6
    		      
    9
    		      
    8
    		  
     
    d.          Salary and Benefits to key officers:

       
    Year ended December 31,
    		  
       
    2017
    		    
    2016
    		    
    2015
    		  
                       
    Salary and related benefits
    		  
    $
    1,673
    		    
    $
    1,714
    		    
    $
    1,849
    		  
    Share-based compensation
    		    
    959
    		      
    1,467
    		      
    2,254
    		  
                             
       
    $
    2,632
    		    
    $
    3,181
    		    
    $
    4,103
    		  
    Number of people that received salary and benefits
    		    
    7
    		      
    10
    		      
    8
    		  

    e.
    Transactions:
     
    For the year ended December 31, 2017
     
       
    Key officers
    		    
    Certain shareholder
    		  
                 
    Revenues
    		  
    $
    -
    		    
    $
    (2,247
    )
    Cost of revenues
    		    
    141
    		      
    (948
    )
    Research and development expenses
    		    
    1,061
    		      
    -
    		  
    Business development expenses
    		    
    547
    		      
    -
    		  
    General and administrative expenses
    		    
    883
    		      
    -
    		  
                     
       
    $
    2,632
    		    
    $
    (3,195
    )
     
    For the year ended December 31, 2016
     
       
    Key officers
    		    
    Certain shareholders
    		  
                 
    Revenues
    		  
    $
    -
    		    
    $
    (5,058
    )
    Cost of revenues
    		    
    104
    		      
    (782
    )
    Research and development expenses
    		    
    1,286
    		      
    -
    		  
    Business development expenses
    		    
    710
    		      
    -
    		  
    General and administrative expenses
    		    
    1,081
    		      
    -
    		  
                     
       
    $
    3,181
    		    
    $
    (5,840
    )
     
    For the year ended December 31, 2015
     
       
    Key officers
    		    
    Certain shareholders
    		  
                 
    Revenues
    		  
    $
    -
    		    
    $
    (10,095
    )
    Cost of revenues
    		    
    544
    		      
    (656
    )
    Research and development expenses
    		    
    1,194
    		      
    -
    		  
    Business development expenses
    		    
    874
    		      
    -
    		  
    General and administrative expenses
    		    
    1,491
    		      
    -
    		  
                     
       
    $
    4,103
    		    
    $
    (10,751
    )